Vinge advises Bridgepoint in its agreement to acquire a significant controlling stake in Safe Life, a global leader in the distribution of automated external defibrillators (AEDs), in a transaction that values the company at c. €500 million.

Headquartered in Stockholm, Safe Life operates across North America and Europe and is a market leader in a highly fragmented and fast-growing sector. The company equips communities and workplaces with lifesaving AEDs supported by ongoing services, including CPR training, maintenance and replacement parts such as pads and batteries to enable a fast and effective response in an emergency.

Bridgepoint will partner with Safe Life’s founders and existing institutional investors including Byggmästaren, Bonnier Capital and Swedbank Robur, all of whom are materially reinvesting alongside Bridgepoint.

The transaction is subject to customary regulatory approvals.

Vinge’s team consisted mainly of Daniel Rosvall, Samra Tesser, Johanna Hamrefält, Sara Hammond and Oliwer Vidarsson (M&A), Albert Wållgren, Josefine Lanker, Calle Tengwall Pagels and Gabriel Chabo (Banking and Finance), Mario Saad, Filippa Eriksson and Carla Håkansson (Commercial Agreements, IT and GDPR), Christoffer Nordin (Regulatory Permits), Simon Söderholm and Viktor Lundberg (Employment), Ian Jonson (IP), Hanna Kövamees and Wilma Hellman (Real Estate and Environment), Sebastian Örndahl, Fredrik Hellström and Hilda Ivarsson (FDI), Julia Ulander Kull (Transaction Support Coordinator).

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026